Education
About Us
Working with TipRanks
Follow Us
Alector Inc (ALEC)
NASDAQ:ALEC
ALEC Stock Chart & Stats
$1.92
-$0.09(-4.55%)
At close: 4:00 PM EST
$1.92
-$0.09(-4.55%)
Day’s Range― - ―
52-Week Range$0.87 - $3.40
Previous CloseN/A
Volume194.31K
Average Volume (3M)1.37M
Market Cap
$200.84M
Enterprise Value$50.46M
Total Cash (Recent Filing)$291.11M
Total Debt (Recent Filing)$37.88M
Price to Earnings (P/E)―
Beta2.08
Next Earnings
Mar 03, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding109,151,474
10 Day Avg. Volume973,682
30 Day Avg. Volume1,366,257
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.44
Price to Sales (P/S)1.82
P/FCF Ratio-0.79
Enterprise Value/Market Cap0.25
Enterprise Value/Revenue0.73
Enterprise Value/Gross Profit2.23
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$2.10Price Target Upside9.38% Upside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
ABC Platform PotentialThe Alector Brain Carrier (ABC) platform enables delivery of antibodies, enzymes, and siRNA into the brain, creating a differentiated capability that could attract pharma partnerships or non-dilutive collaborations.
Planned IND Filings And Pipeline ValidationPlanned IND filings for AL137 and AL050 could validate the ABC platform if either program advances into clinical testing and demonstrates CNS target engagement.
PROGRESS-AD Interim ReadoutA successful interim analysis from the PROGRESS-AD Phase II study of nivisnebart could provide clinically meaningful biomarker and efficacy signals that support re-rating of the Alzheimer’s program.
Bears Say
Phase III INFRONT-3 FailureThe Phase III INFRONT-3 failure to show clinical benefit highlights the risk that biomarker increases may not translate into meaningful patient outcomes for progranulin-based therapies.
Progranulin Target UncertaintyA disconnect between elevated progranulin levels and lack of clinical improvement casts doubt on the SORT1 target and the broader translatability of progranulin-based approaches.
Workforce Reductions And Operational RiskLarge workforce reductions and pipeline narrowing signal operational strain and increase uncertainty around the company's ability to advance multiple programs.
Alector News
ALEC FAQ
What was Alector Inc’s price range in the past 12 months?
Alector Inc lowest stock price was $0.87 and its highest was $3.40 in the past 12 months.
What is Alector Inc’s market cap?
Alector Inc’s market cap is $200.84M.
When is Alector Inc’s upcoming earnings report date?
Alector Inc’s upcoming earnings report date is Mar 03, 2026 which is in 47 days.
How were Alector Inc’s earnings last quarter?
Alector Inc released its earnings results on Nov 06, 2025. The company reported -$0.34 earnings per share for the quarter, beating the consensus estimate of -$0.408 by $0.068.
Is Alector Inc overvalued?
According to Wall Street analysts Alector Inc’s price is currently Undervalued.
Does Alector Inc pay dividends?
Alector Inc does not currently pay dividends.
What is Alector Inc’s EPS estimate?
Alector Inc’s EPS estimate is -0.38.
How many shares outstanding does Alector Inc have?
Alector Inc has 109,151,474 shares outstanding.
What happened to Alector Inc’s price movement after its last earnings report?
Alector Inc reported an EPS of -$0.34 in its last earnings report, beating expectations of -$0.408. Following the earnings report the stock price went down -1.538%.
Which hedge fund is a major shareholder of Alector Inc?
Currently, no hedge funds are holding shares in ALEC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alector Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.10 (9.38% Upside)
$2.10 (9.38% Upside)
Blogger Sentiment
Neutral
ALEC Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 158.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $212.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 8.6%
Last 30 Days ▲ 8.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.26%
12-Months-Change
Fundamentals
Return on Equity
-121.98%
Trailing 12-Months
Asset Growth
-35.03%
Trailing 12-Months
Company Description
Alector Inc
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
ALEC Stock 12 Month Forecast
Average Price Target
$2.10
▲(9.38% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---